Oncology AI: Decoding the Clinical Decision Ecosystem

Precision oncology has huge potential, but it’s also a money pit if you don’t know where to look. The field is a tangle of genomic data, clinical records, and AI tools, and figuring out how it all connects is the key to making smart investments and, more importantly, helping patients. This is a look at the critical links between genomic sequencing, electronic health records (EHRs), and the AI platforms that try to turn a firehose of data into something an oncologist can actually use.

The Multimodal Data Challenge in Precision Oncology

The main problem in precision oncology is getting all the different types of data to work together. A genomic sequence by itself isn’t enough. To make any sense of it, you need the clinical context, the patient’s history, their pathology reports, the imaging scans, and how they’ve responded to previous treatments. You’re dealing with a massive and messy pile of information, which is why you need serious software platforms just to structure and standardize it all. This is exactly where AI-native companies are trying to build their defensive business moats. The National Cancer Institute (NCI) has been pushing for complete data sharing and integration for years to speed up cancer research, as you can see in the NCI data sharing guidelines. The groundwork laid by organizations like the NCI creates the opportunity for commercial companies to come in and build tools that can exploit these complex data relationships for profit.

Connecting Genomic Insights with Clinical Reality: Tempus AI and Franklin by QIAGEN

Let’s look at Tempus AI and Franklin by QIAGEN to see how this data generation, interpretation, and clinical use actually plays out. These companies are different but connected parts of the data value chain in precision oncology.

Tempus AI: Structuring the Multimodal Oncology Data Field

Tempus AI’s business is built on structuring multimodal genomic and clinical data. They do this by collecting huge amounts of real-world data, including both genomic sequences and de-identified clinical information that they get from their network of healthcare providers. The sheer size of their patient database is what separates them from many others and is what they use to train and improve their AI algorithms. As their sequencing volume grows, their datasets get richer, creating a flywheel effect. For an oncologist, the pitch from Tempus AI is a unified view of a patient’s cancer, where they merge genomic findings with clinical history to suggest specific treatments or find a matching clinical trial. The whole thing is powered by a data pipeline that’s designed to take raw, messy EHR data and genomic reports and turn them into a clean, structured format you can actually query. The end result is often a report used for clinical decision support, giving doctors evidence-based recommendations while they’re with a patient.

Franklin by QIAGEN: Powering Variant Interpretation

While Tempus AI is focused on structuring broad sets of data, Franklin by QIAGEN sells software that does one very specific thing well: variant interpretation. You need this kind of software to translate the incredibly complex output of a genomic sequencer into something that has clinical meaning. So, where Tempus aggregates and contextualizes data, Franklin provides the specialized analytical horsepower to figure out what a specific genetic mutation actually means for the patient. Franklin is now part of QIAGEN, a major player in molecular diagnostics. The relationship between these kinds of companies is often practical and workflow-driven. For example, a genomic lab might use Franklin’s software to interpret its sequencing results. That interpreted report then becomes a piece of clinical data that a platform like Tempus AI might ingest and integrate into a larger patient profile. This flow of data, from raw sequence, to interpreted variant, to a full patient record, shows how all these different parts have to work together. You can see the progress in both data integration and variant interpretation every year in the ASCO annual meeting abstracts and other peer-reviewed research.

Identifying High-Value Nodes for Investment in Precision Medicine Workflows

If you’re a venture capitalist in life science tools or precision medicine, you have to understand these data workflows to spot good investments. The real competitive advantages are built on proprietary data networks and the quality of the algorithms that pull insights from that data. What should you be looking at when evaluating a company? * Clinical Validation Score: How well has the AI been tested in actual clinics? You’re looking for published outcomes data that shows it improved patient results or made the hospital more efficient. Anything less is just a promise.

• Regulatory Risk Rating: Compliance is not optional. A company must follow regulations like the HHS AI transparency guidelines. A company with a clear regulatory strategy (like a 510(k) or De Novo submission) and a serious Quality Management System (QMS / ISO 13485) is a much safer bet. For the newer adaptive AI models, the ability to manage algorithmic changes with a Predetermined Change Control Plan (PCCP) is a huge plus, especially with the FDA’s framework for PCCPs finalized in August 2025.
• Payer Penetration Depth: Can they actually get paid for this? Securing reimbursement, either through established CPT codes (Category I & III) or other routes like NTAP (New Technology Add-On Payment), is a huge sign of commercial viability.
• Published Outcomes Data: This is the proof. Hard evidence of better clinical trial matching, higher diagnostic accuracy, or better treatment response prediction is what creates real commercial value and drives adoption. Companies that are good at building complete patient databases, growing their sequencing volume, and connecting genomic data to real-world outcomes are the ones building strong data moats. It isn’t about having the most data, it’s about the quality of the data and the proprietary methods used to structure and interpret it. The best returns will come from investing in companies that can connect complex genomic information to everyday clinical practice while successfully getting through the regulatory maze.
  

  Methodology and Source Note

  A quick note on my sources. This analysis comes from talking with experts who work in this field every day, combined with a review of public information on how these companies operate. The information on company operations and their relationships is pieced together from financial disclosures, scientific papers, and industry reports. It’s all grounded in a review of the key regulatory frameworks and clinical guidelines that govern this work.